Fintel reports that on February 13, 2025, UBS downgraded their outlook for Novartis AG - Depositary Receipt () (NYSE:NVS) ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

Since 2021, there’s been an increase in representation of people from underrepresented and underserved communities in Super ...

U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly ...

The Super Bowl has always been more than a game—it’s a cultural barometer, reflecting how brands engage with audiences at the ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

UBS analyst Matthew Weston downgraded Novartis (SIX:NOVN) shares from Buy to Neutral and reduced the price target from CHF111.00 to CHF104.00. The adjustment reflects a reassessment of the ...

The chemical manufacturer affected natural resources to the tune of over $1 billion and contributed to a rise in cancer cases ...